.png)
Fully Embracing AI: HB Unveils New Strategy at CMEF
In an era where AI continues to reshape industries and new quality productive forces rapidly emerge, Haier Biomedical — a subsidiary of Incaier — unveiled its comprehensive artificial intelligence (AI)-driven strategy focused on "AI+ Large Model Applications" at CMEF on April 8. The newly launched strategy aims to deeply integrate cutting-edge AI technologies into life science applications, thereby accelerating intelligent upgrades across the industry and transforming the user experience.
The launch of this AI-driven strategy marks Haier Biomedical's official entry into a new phase of deep integration between life sciences and AI. It signifies not only a major milestone in the company's own development, but also a pioneering step forward in the digital transformation of the broader industry — one that holds the potential to drive widespread innovation and reform.
Strategic Upgrade to AI+: Embracing the Trend and Accelerating Transformation with AI as the Core Engine
Coinciding with its 20th anniversary, Haier Biomedical has officially entered a new stage of development centered on "AI+ Large Model Applications," with AI serving as the core engine. This strategic upgrade includes the development of large model-based technologies and solutions, such as the innovative Kuidou biobank model and the Laboratory Digital Twin System. AI will be deeply integrated across all phases — from product R&D and manufacturing to marketing and customer service — empowering the company to build AI-powered solutions that enhance efficiency, optimize user experience, and deliver greater added value. At the core of the strategy is the Incaier Brain, a foundational life sciences platform powered by the industry-specific large model IncGPT-BiolifeSci, which combines intelligent agent technology with comprehensive, scenario-based solutions. Functioning as an intelligent "central nervous system," the Incaier Brain connects a wide array of smart terminal devices, enabling them to perceive, analyze, and make decisions. The system transforms isolated hardware into intelligent, collaborative tools, advancing solution innovation in precision, accessibility, automation, and intelligence. Haier Biomedical is also advancing operational upgrades across the entire process through AI, driven by three core modules: smart interaction, smart delivery, and smart service. These modules enable precise interpretation of diverse user inputs during solution interactions, accurate matching of client needs for customized services, demand forecasting and intelligent scheduling during delivery, and proactive, data-driven service offerings. Together, they deliver a personalized, integrated, and efficient end-to-end user experience. Scenario-Based AI+ Upgrade: Reconstructing Intelligence and Expanding the AI Application Matrix In the AI+ Smart biobank scenario, the newly released fourth-generation biobank, U-Vault Flex80, features the Kuidou AI autonomous decision-making model and AI-powered, low-temperature, high-speed transmission control. In emergency situations, it enables automated, exposure-free sample transfers while maintaining ultra-low-temperature overload protection. Its AI-driven visual recognition and bionic multi-robot arm control also enable precise sample storage and retrieval, achieving breakthroughs in intelligence, safety, and throughput. In the AI+ Smart Hospital scenario, Haier Biomedical has launched a fully automated cytotoxic drug compounding robot that digitizes the entire medication workflow — from storage and transfer to preparation, dispensing, and administration. This system reduces the risk of mismatches and human error, minimizes medical personnel's exposure to hazardous substances, and ensures full data traceability, ultimately freeing up caregivers' time so they can focus more on patient care. In the AI+ Smart Blood Management scenario, the company integrates three core modules — intelligent centrifugation, precise separation, and efficient thawing — to create a full life-cycle intelligent solution covering every stage from collection and storage to distribution and administration. This end-to-end digitization of blood component processing empowers blood supply institutions to improve operational efficiency, reduce errors, and ensure that each unit of blood is traceable, safe, and fully controlled. Looking ahead, the implementation of Haier Biomedical's AI-empowered full product portfolio strategy is set to transform how users interact with equipment — enhancing operational efficiency, reducing costs, and ultimately accelerating research and innovation. Ecosystem AI+ Upgrade: Advancing International Strategy and Expanding Co-Creation to Accelerate Innovation The AI-driven digital transformation of life sciences is a complex, large-scale endeavor that requires an open and collaborative ecosystem that creates win-win outcomes. To this end, Haier Biomedical has established an open R&D system that actively involves users in research, testing, and application. This deep co-creation with users and ecosystem partners continues to strengthen the company’s industry-leading innovation capabilities. Leveraging its distinct R&D model of "independent development, co-research, acquisition, and incubation," Haier Biomedical has established an integrated industry–academia–research innovation consortium, forming strategic partnerships with leading ecosystem players, including platforms focused on AI digital human development, AI application development, AI-powered medical services, and large AI models for scientific research. Through its Med-Tech innovation platform "HaiYiHui," Haier Biomedical rapidly engages with top-tier industry resources to assemble a collaborative R&D network of industry experts, academic institutions, and co-creative users, accelerating the translation of ideas into applications. Furthermore, as technological innovation continues to converge with AI, global demand for smarter life sciences solutions is rising. With operations in over 150 countries and regions, Haier Biomedical is strengthening its user-centric global market system and advancing its "one country, one strategy" localization approach. The company is building regional delivery capabilities and local technical support mechanisms to better understand and meet local user needs. This approach enables Haier Biomedical to expand beyond low-temperature storage products and drive the development of a broad range of integrated solutions, enhancing its ability to provide scenario-based solutions that are more interactive and customizable. The Future Is Here: AI Takes the Lead With the launch of its comprehensive AI strategy, Haier Biomedical is embedding AI deeply into life science applications, ushering in a new era of digital intelligence for the industry. This also represents a meaningful contribution of Chinese wisdom and strength to the global pursuit of human health.
